Last reviewed · How we verify
NCT01485549: BIOAMS
Oligomeric Alpha-synuclein in Multiple System Atrophy
trial in Multiple System Atrophy (MSA) in 48 participants. Completed in 21 November 2018.
20 November 2018
Quick facts
| Lead sponsor | University Hospital, Bordeaux |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 48 |
| Start date | 26 November 2012 |
| Primary completion | 20 November 2018 |
| Estimated completion | 21 November 2018 |
| Sites | 1 location across France |
Conditions studied
- Multiple System Atrophy (MSA) — all drugs for Multiple System Atrophy (MSA) →
Sponsor
University Hospital, Bordeaux
Who can join
30 and older, any sex, with Multiple System Atrophy (MSA). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF) and plasma levels.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
Poggiolini I, Gupta V, Lawton M, Lee S, et al · · 2022 · cited 161× · PMID 34894214 · DOI 10.1093/brain/awab431 -
Multiple system atrophy: an update and emerging directions of biomarkers and clinical trials.
Liu M, Wang Z, Shang H. · · 2024 · cited 19× · PMID 38483626 · DOI 10.1007/s00415-024-12269-5 -
Diagnosing multiple system atrophy: current clinical guidance and emerging molecular biomarkers.
Goolla M, Cheshire WP, Ross OA, Kondru N. · · 2023 · cited 12× · PMID 37840912 · DOI 10.3389/fneur.2023.1210220
Verify or expand the search:
- PubMed search for NCT01485549
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Multiple System Atrophy (MSA)
Currently open trials in the same condition.
- NCT07446894 — MSA-01 in Multiple System Atrophy · Phase 3 · recruiting
- NCT06949865 — AI-Enhanced Optimization of Acute Levodopa Challenge Test · recruiting
- NCT05923866 — A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy · Phase 2 · active not recruiting
Other University Hospital, Bordeaux trials
Trials by the same sponsor.
- NCT07506928 — NEURO - Prognostication Using Late Somatosensory Evoked - Potentials · NA · not yet recruiting
- NCT07524036 — Impact of a Nursing Educational Consultation on the Patient's Adherence to Their Post-stroke Care Plan. · NA · not yet recruiting
- NCT07527494 — Digital MEDIcal TWIN for the Prediction of Arrhythmic Sudden Cardiac Death After a Myocardial Infarction · NA · not yet recruiting
- NCT07527442 — Efficacy and Safety of Circumcision Alone on Risk of Febrile Urinary Tract Infections in Boys With Posterior Urethral Va · Phase 2 · not yet recruiting
- NCT07478523 — FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01485549 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Bordeaux
- Last refreshed: 27 June 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01485549.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing